These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27184730)

  • 1. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
    Volterrani M; Iellamo F; Senni M; Piepoli MF
    Int J Cardiol; 2017 Jan; 226():132-135. PubMed ID: 27184730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
    Docherty KF; McMurray JJV
    Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
    Xie W; Zheng F; Song X; Zhong B; Yan L
    Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.
    Volpe M; Santolamazza C; Tocci G
    Curr Cardiol Rep; 2016 Dec; 18(12):127. PubMed ID: 27796865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
    Leong DP; McMurray JJV; Joseph PG; Yusuf S
    J Am Coll Cardiol; 2019 Aug; 74(5):683-698. PubMed ID: 31370961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction.
    Nasrallah D; Abdelhamid A; Tluli O; Al-Haneedi Y; Dakik H; Eid AH
    Pharmacol Res; 2024 Jun; 204():107210. PubMed ID: 38740146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
    Sutanto H; Dobrev D; Heijman J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
    Díez J
    Eur J Heart Fail; 2017 Feb; 19(2):167-176. PubMed ID: 27766748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
    Rossignol P; Zannad F; Pitt B;
    Int J Cardiol; 2014 Dec; 177(3):731-3. PubMed ID: 25465821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    D'Elia E; Iacovoni A; Vaduganathan M; Lorini FL; Perlini S; Senni M
    Eur J Heart Fail; 2017 Jun; 19(6):710-717. PubMed ID: 28326642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New therapeutic era in heart failure with reduced ejection fraction: Which population of French patients is concerned?].
    Juillière Y; Ferrières J
    Ann Cardiol Angeiol (Paris); 2016 Sep; 65(4):237-9. PubMed ID: 27242321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure.
    Fu S; Chang Z; Luo L; Deng J
    Curr Top Med Chem; 2019; 19(20):1850-1866. PubMed ID: 31448711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.
    Hua Y; Wang I; Liu B; Kelly DJ; Reid C; Liew D; Zhou Y; Wang BH
    Future Cardiol; 2017 Mar; 13(2):103-115. PubMed ID: 27892684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARNi: A Novel Approach to Counteract Cardiovascular Diseases.
    Volpe M; Rubattu S; Battistoni A
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost.
    Manolis AS; Manolis TA; Manolis AA; Melita H
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):21-36. PubMed ID: 29926350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
    von Lueder TG; Sangaralingham SJ; Wang BH; Kompa AR; Atar D; Burnett JC; Krum H
    Circ Heart Fail; 2013 May; 6(3):594-605. PubMed ID: 23694773
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.
    Vaduganathan M; Fonarow GC; Greene SJ; Devore AD; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
    J Card Fail; 2022 Feb; 28(2):191-201. PubMed ID: 34428591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.